GemPharmatech Co (SHSE:688046) Research & Development: ¥93.7 Mil (TTM As of Mar. 2026)


SHSE:688046 GemPharmatech Co Ltd SHSE:688046
95 GF Score
Price ¥24.18
GF Value ¥19.37
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is GemPharmatech Co Research & Development?

GemPharmatech Co SHSE:688046 -0.08% 95 Research & Development is ¥93.7 Mil as of Mar. 2026. GuruFocus rates SHSE:688046 with a GF Score™ of 95/100 and a GF Value™ of ¥19.37 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. GemPharmatech Co's Research & Development for the three months ended in Mar. 2026 was ¥19.9 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥93.7 Mil.

GemPharmatech Co  (SHSE:688046) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

GemPharmatech Co Research & Development Related Terms

GemPharmatech Co Research & Development Historical Data

* Premium members only.

The historical data trend for GemPharmatech Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GemPharmatech Co Research & Development Chart

GemPharmatech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 55.20 82.93 96.60 87.13 92.06

GemPharmatech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.26 21.12 22.62 30.07 19.87
SHSE:688046
95GF Score
GemPharmatech Co Ltd SHSE:688046
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GemPharmatech Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥93.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥93.7 Mil mean?
GemPharmatech Co (SHSE:688046) has a Research & Development of ¥93.7 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on GemPharmatech Co and its competitors.
Is GemPharmatech Co's Research & Development too high?
GemPharmatech Co's current Research & Development is ¥93.7 Mil. Overall, GemPharmatech Co has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GemPharmatech Co's Research & Development compare to VRTX and REGN?
GemPharmatech Co's Research & Development of ¥93.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on GemPharmatech Co and its competitors. GemPharmatech Co's current Research & Development is ¥93.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GemPharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, GemPharmatech Co (SHSE:688046) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥19.37, compared to a current price of ¥24.18 — trading 24.8% above its estimated fair value. The current Research & Development is ¥93.7 Mil. GemPharmatech Co's overall GF Score™ is 95/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For GemPharmatech Co (SHSE:688046), the current Research & Development is ¥93.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GemPharmatech Co (SHSE:688046) Overvalued in 2026?

Based on GuruFocus' analysis, GemPharmatech Co stock appears to be overvalued. The current stock price of ¥24.18 is trading 24.8% above its estimated GF Value™ of ¥19.37. GuruFocus considers GemPharmatech Co to be Modestly Overvalued.

Key valuation signals for SHSE:688046:

  • Research & Development: ¥93.7 Mil
  • GF Value™: ¥19.37 vs. price of ¥24.18 (24.8% above fair value)
  • GF Score™: 95/100 with 8 warning signs

No single metric tells the full story. See the SHSE:688046 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GemPharmatech Co Business Description

Address No. 12, Xuefu Road, Jiangbei New District, Jiangsu Province, Nanjing, CHN, 210032
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
95GF Score

Get the complete analysis for SHSE:688046

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥24.18
Price
¥19.37
GF Value